Javier San Martin
Chief Tech/Sci/R&D Officer en ATHIRA PHARMA, INC. .
Fortuna: 6 M $ al 31/03/2024
Perfil
En la actualidad, Javier San Martín es Director Médico de Arrowhead Pharmaceuticals, Inc. Anteriormente ocupó el cargo de Director Ejecutivo del Área Terapéutica Ósea en Amgen, Inc., Director en Eli Lilly & Co., Vicepresidente Senior de Desarrollo Clínico Global en Ultragenyx Pharmaceutical, Inc. y Vicepresidente Senior de Desarrollo Clínico en Alder Biopharmaceuticals, Inc. Se doctoró en la Universidad de Buenos Aires.
Participaciones conocidas en empresas públicas
| Empresa | Fecha | Número de acciones | Valoración | Fecha de valoración |
|---|---|---|---|---|
| 10/01/2024 | 198 497 ( 0.16% ) | 6 M $ | 31/03/2024 |
Cargos activos de Javier San Martin
| Empresas | Cargo | Inicio |
|---|---|---|
| ATHIRA PHARMA, INC. | Chief Tech/Sci/R&D Officer | 15/04/2024 |
Antiguos cargos conocidos de Javier San Martin.
| Empresas | Cargo | Fin |
|---|---|---|
| ARROWHEAD PHARMACEUTICALS, INC. | Chief Tech/Sci/R&D Officer | 01/02/2024 |
| ULTRAGENYX PHARMACEUTICAL INC. | Corporate Officer/Principal | 01/11/2019 |
| AMGEN INC. | Corporate Officer/Principal | - |
| ELI LILLY AND COMPANY | Corporate Officer/Principal | - |
| ALDER BIOPHARMACEUTICALS, INC. | Corporate Officer/Principal | - |
Formación de Javier San Martin.
| University of Buenos Aires School of Medicine | Doctorate Degree |
Experiencias
Funciones ocupadas
Activas
Inactivas
Empresas cotizadas
Empresas privadas
Relaciones
Relaciones de 1er grado
Empresas vinculadas al 1er grado
Hombre
Mujer
Administradores
Ejecutivos
Empresas relacionadas
| Empresas cotizadas | 5 |
|---|---|
| AMGEN INC. | Health Technology |
| ELI LILLY AND COMPANY | Health Technology |
| ARROWHEAD PHARMACEUTICALS, INC. | Health Technology |
| ULTRAGENYX PHARMACEUTICAL INC. | Health Technology |
| ATHIRA PHARMA, INC. | Health Technology |
| Empresas privadas | 1 |
|---|---|
Lundbeck Seattle BioPharmaceuticals, Inc.
 Lundbeck Seattle BioPharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Lundbeck Seattle BioPharmaceuticals, Inc. is a clinical-stage biopharmaceutical company, which focuses on transforming the migraine treatment paradigm through the discovery, development and commercialization of novel therapeutic antibodies. Its product includes Eptinezumab, is an investigational monoclonal antibody (mAb) that inhibits calcitonin gene-related peptide (CGRP) and is currently in late-stage clinical development for the prevention of migraine. The company was founded by Randall C. Schatzman, Mark J. Litton, and John A. Latham in January 2004 and is headquartered in Bothell, WA. | Health Technology |
- Bolsa de valores
- Insiders
- Javier San Martin
